As filed with the U.S. Securities and Exchange Commission on February 10, 2026. Registration No. 333-292285 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ––––––––––––––––––––––––––––––––––––––– AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ––––––––––––––––––––––––––––––––––––––– Brookline Capital Acquisition Corp II (Exact name of registrant as specified in its charter) ––––––––––––––––––––––––––––––––––––––– | Cayman Islands | 6770 | N/A | | - ...

Core Insights - Microchip Technology is advancing edge AI system development by providing full-stack solutions that integrate silicon, software, tools, and production-ready applications, aimed at enhancing real-time inferencing and decision-making in various sectors [1][2] Group 1: Product Offerings - The new solutions transform Microchip's microcontrollers (MCUs) and microprocessors (MPUs) into comprehensive platforms for secure, efficient, and scalable edge intelligence [2] - Microchip's full-stack application solutions include pre-trained models and application code that can be modified for different environments, utilizing both Microchip's tools and those from partners [3][4] - The MPLAB® X Integrated Development Environment (IDE) and MPLAB ML Development Suite enable rapid prototyping and deployment of AI models, facilitating a seamless transition from simple tasks to high-performance applications [4] Group 2: Market Trends and Industry Position - According to IoT Analytics, embedding edge AI capabilities directly into MCUs is a leading industry trend that enhances data privacy and reduces reliance on cloud infrastructure [7] - Microchip's initiative aligns with this trend by offering a platform that supports both software AI accelerators and integrated hardware acceleration across various devices [7] Group 3: Applications and Use Cases - Applications of Microchip's edge AI solutions include detection of electrical arc faults, condition monitoring for predictive maintenance, facial recognition with liveness detection, and keyword spotting for command-and-control interfaces [8] Group 4: Customer Engagement and Support - Microchip is actively collaborating with customers on its full-stack application solutions, providing model training and workflow support, and is also engaging with partners to offer additional deployment-ready options [9]

NYSE: GWW Q4 2025 Earnings Call February 3, 2026 © 2026 W.W. Grainger, Inc. Safe Harbor Statement and Non-GAAP Financial Measures All statements in this communication, other than those relating to historical facts, are "forward-looking statements" under the federal securities laws. Forward-looking statements can generally be identified by their use of terms such as "anticipate," "estimate," "believe," "expect," "could," "forecast," "may," "intend," "plan," "predict," "project," "will," or "would," and simil ...

Core Insights - Keysight Technologies and Point2 Technology have formed a strategic collaboration to validate next-generation multi-terabit interconnects aimed at addressing connectivity bottlenecks in AI and ML data centers [1][2] Group 1: Technology and Performance - Point2's e-Tube™ technology utilizes RF data transmission over plastic waveguide, offering up to 10x longer reach than traditional copper at a comparable cost, while being 3x lower in power and cost, and 1,000x lower in latency compared to optical solutions [2] - The collaboration focuses on validating interconnects that meet the stringent reliability and performance requirements of hyperscalers, with Keysight providing a comprehensive validation framework [3][4] Group 2: Tools and Capabilities - Keysight's high-speed digital test solutions, including the M8050A High-Performance Bit Error Ratio Tester (BERT) and DCA-X Sampling Oscilloscopes, are essential for generating and analyzing complex 120 GBaud PAM4 signals necessary for achieving 1.6 Terabit speeds [4] - The partnership enables early research and development on 3.2T interfaces by leveraging Keysight's unique 448 Gbps electrical signal generation capabilities [3] Group 3: Industry Impact - The collaboration is expected to accelerate Point2's e-Tube product development cycles, providing confidence in the technology's validation as it engages with leading hyperscaler customers globally [5] - Keysight emphasizes the need for disruptive innovation in physical interconnects to meet the demands of AI scale-up architectures, positioning itself as a trusted source for measurement truth in the industry [5]

Financial Data and Key Metrics Changes - In Q4 2025, revenue reached $3.65 billion, a 44% increase year-over-year, exceeding guidance [8][9] - Adjusted EPS for the quarter was $1.89, up 70% from the previous year [9] - Full-year revenue for 2025 was $12.4 billion, representing a 28% growth, while adjusted EPS was $6.05, a 56% increase [5][6] - Adjusted operating margin for Q4 was 7.7%, marking the strongest performance in company history [5][9] - Adjusted ROIC was 43%, up 14 percentage points compared to the prior year [10] Business Segment Data and Key Metrics Changes - ATS segment revenue was $795 million, a 1% decline, while CCS segment revenue was $2.86 billion, up 64% [10] - Communications end market revenue increased by 79%, driven by demand for 800G networking switches [11] - Enterprise end market revenue grew by 33%, supported by AI/ML compute programs [11] - ATS segment margin improved to 5.3%, while CCS segment margin was 8.4% [12] Market Data and Key Metrics Changes - The CCS segment accounted for 78% of total company revenue in Q4 [10] - Three customers accounted for 36%, 15%, and 12% of total revenue in Q4 [12] - Inventory balance at the end of Q4 was $2.19 billion, a sequential increase of $141 million [13] Company Strategy and Development Direction - The company plans to increase capital expenditures to approximately $1 billion in 2026 to support growth [14][15] - Investments will focus on expanding capacity in the U.S. and Thailand to meet customer demand [16][17] - The company aims to align its global footprint with customer capacity roadmaps, particularly in data center infrastructure and AI capabilities [15][18] - The outlook for 2026 revenue is raised to $17 billion, with adjusted EPS expected to be $8.75, reflecting strong demand [23][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the 2026 outlook, citing strong customer demand and a robust pipeline of growth opportunities [23][25] - The company anticipates continued growth in the CCS segment, driven by hyperscaler demand for networking technologies [26][27] - Management acknowledged macro uncertainties but emphasized a strong demand outlook [35][39] Other Important Information - The company generated $156 million in free cash flow in Q4, totaling $458 million for the year [13] - The gross debt to non-GAAP trailing twelve-month Adjusted EBITDA leverage ratio improved to 0.7 turns [19] - The company repurchased approximately 132,000 shares for $36 million during the quarter [20] Q&A Session Summary Question: Clarification on revenue and EPS guidance for fiscal 2026 - Management confirmed confidence in the 2026 outlook, noting customer forecasts exceed guidance [34] Question: Concerns about funding for future AI-related projects - Management stated that the build-out is based on booked business, with minimal risk of programs not materializing [37] Question: CapEx investment and its impact on revenue growth - Management indicated that current investments are based on booked business and will support growth into 2027 [47] Question: Margin trajectory with enterprise growth - Management expects strong operating leverage and does not foresee significant margin compression despite enterprise growth [55] Question: Supply chain and inflation impact on margins - Management is comfortable with the supply chain and does not anticipate significant margin compression from inflation [104]

Core Viewpoint - NetraMark Holdings Inc. has announced the appointment of Lawrence Guy to its Board of Directors, enhancing the Board's expertise in capital markets and investment management [1][2]. Group 1: Board Appointment - Lawrence Guy's appointment is expected to strengthen the Board with his extensive experience in capital markets, investment management, and public-company governance [2]. - Mr. Guy is currently a Managing Director at Next Edge Capital, focusing on strategic partnerships and evaluating new investment opportunities [2]. - His previous roles include Vice President at Purpose Investments and Portfolio Manager at Aston Hill Financial Inc., showcasing a strong background in financial leadership and corporate development [3]. Group 2: Educational Background and Current Roles - Mr. Guy holds a BA in Economics from the University of Western Ontario and is a Chartered Financial Analyst [4]. - He currently serves as a director for several companies, including Emerita Resources Corp., Lithium Ionic Corp., Nobel Resources Corp., and Halcones Precious Metals Corp. [4]. Group 3: Company Overview - NetraMark is focused on developing Generative Artificial Intelligence (Gen AI) and Machine Learning (ML) solutions for the pharmaceutical industry [5]. - The company's innovative topology-based algorithm allows for the parsing of patient data into relevant subsets, enabling accurate disease segmentation and patient classification for drug sensitivity and treatment efficacy [5].

Summary of Fortrea Holdings Conference Call Company Overview - **Company Name**: Fortrea Holdings - **Industry**: Contract Research Organization (CRO) - **Background**: Fortrea was spun out from Labcorp in 2023, with roots tracing back to Covance, which Labcorp acquired in 2015. The company focuses on advancing clinical development and providing innovative solutions for drug development [2][3]. Core Points and Arguments - **Value Proposition**: Fortrea positions itself as a pure-play global CRO with decades of experience, capable of serving a diverse client base, from large pharmaceutical companies to small biotech firms [4][5]. - **Market Environment**: The overall market for pharmaceutical R&D investments is cautiously optimistic, with expected growth rates of approximately 3%-4% in the near term, driven by big pharma's renewed focus on R&D and improvements in biotech funding [6][24][26]. - **Service Offerings**: Fortrea provides a comprehensive suite of services across the clinical trial continuum, including clinical operations, data management, biostatistics, and consulting services, with expertise in over 20 therapeutic areas [8][12]. - **Technological Integration**: The company is modernizing study delivery by leveraging AI and machine learning to enhance productivity and quality in clinical trials [5][14]. - **Client Relationships**: Fortrea emphasizes building strong, long-term relationships with clients, which is reflected in its balanced client base of approximately 50% large pharma and 50% biotech [13][39]. Important but Overlooked Content - **Operational Focus**: The management team is concentrating on three pillars of excellence: commercial, operational, and financial, to drive sustained revenue growth and margin expansion [15][17]. - **Cost Management**: Fortrea aims to achieve approximately $150 million in gross cost savings, with a focus on right-sizing the organization while also driving revenue growth [32][33]. - **Market Trends**: There is a shift towards hybrid outsourcing models, particularly among mid-sized biotech companies, which Fortrea is well-positioned to accommodate [28]. - **Pricing Discipline**: The CRO market is competitive, and while pricing plays a significant role in FSP (Functional Service Provider) contracts, Fortrea maintains a focus on quality and team performance over price alone [34][35]. - **Capital Allocation**: Post-spin, Fortrea is focused on improving its debt position and making targeted organic investments to enhance productivity and relevance in the market [36][38]. Conclusion - **Key Message**: Fortrea has successfully transitioned out of its spin-off phase, is focused on execution and customer satisfaction, and is optimistic about returning to sustainable growth as market conditions improve [39].

As filed with the U.S. Securities and Exchange Commission on December 19, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ––––––––––––––––––––––––––––––––––––––– FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ––––––––––––––––––––––––––––––––––––––– Brookline Capital Acquisition Corp II (Exact name of registrant as specified in its charter) ––––––––––––––––––––––––––––––––––––––– | Cayman Islands | 6770 | N/A | | --- | --- | --- | | (State ...

Core Insights - The rise of artificial intelligence (AI) has significantly impacted the technology sector, with companies like Nvidia and Apple benefiting from this trend [1][5]. Company Performance - Nvidia has experienced a remarkable stock surge of 975% over the past three years, driven by high demand for its AI-centric GPUs, while Apple has seen a more modest increase of 95% during the same period [5]. - Apple is expected to enhance its performance in the AI space, with a Wall Street analyst predicting it could outperform Nvidia in the coming year [3][6]. Analyst Insights - Wedbush analyst Dan Ives has raised Apple's price target to $350 from $320, indicating a potential upside of 26% from its recent closing price [6]. - Ives believes that 2026 will be a pivotal year for Apple as it begins to implement a comprehensive AI strategy, highlighted by the hiring of AI expert Amar Subramanya [7][8]. AI Strategy - Subramanya's expertise in AI and machine learning will be crucial for Apple's innovation and future AI features, particularly in enhancing Siri, Apple's voice assistant [9][10]. - A potential partnership with Google for an AI overhaul of Siri could significantly boost Apple's AI ambitions and market interest [9]. Product Performance - Ives notes that iPhone 17 sales are performing well, with expectations for a strong finish to the year due to the holiday season [11]. - Apple's large installed base of 2.4 billion iOS devices, including 1.5 billion iPhones, presents a significant opportunity for growth, potentially increasing the stock value by $75 to $100 per share [12]. Market Capitalization - If Apple reaches the price target of $350, its market cap could rise to $5.17 trillion, surpassing Nvidia's projected market cap of $5.1 trillion if it hits a target of $210 [13][14].

Financial Data and Key Metrics Changes - Revenue for Q3 2025 was $701.3 million, a 3.9% increase compared to the prior year quarter, driven by growth in both clinical pharmacology and clinical development businesses [19][30] - Adjusted EBITDA for the quarter was $50.7 million, down from $64.2 million in the prior year period, primarily due to lower margins related to project mix and increased pass-through costs [23][30] - The company reported a net loss of $15.9 million for Q3 2025, an improvement from a net loss of $18.5 million in the prior year [23] - The book-to-bill ratio improved to 1.13 times, with a backlog exceeding $7.6 billion [5][22] Business Line Data and Key Metrics Changes - The clinical pharmacology business saw increased demand and higher levels of pass-through costs, contributing to revenue growth [19] - The clinical development segment also experienced growth due to new business awards, although it was partially offset by lower fee-for-service (FFP) revenue [19] - Average contract size in clinical pharmacology continues to increase, reflecting expertise in managing complex early-phase clinical trials [9] Market Data and Key Metrics Changes - Demand for services has shown signs of improvement, with growth in clinical trial starts and increased biotech funding in Q3 2025 [6] - Win rates with biotech clients doubled compared to the prior quarter, indicating a positive trend in client engagement [6][37] Company Strategy and Development Direction - The company is focusing on three critical pillars: commercial excellence, operational excellence, and financial excellence, to drive growth and improve margins [15][16] - A renewed focus on client-facing activities and employee engagement has been emphasized, with efforts to deepen relationships with clients and enhance operational efficiency [12][15] - The company is committed to maintaining a healthy balance sheet and financial flexibility, including debt repayment initiatives [7][28] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the improving demand environment and the resilience of biopharma clients, despite competitive pressures [6][40] - The company anticipates continued growth in its backlog and is focused on optimizing its capital structure and cash flow [26][30] - There is a commitment to right-sizing the organization and enhancing operational efficiency to achieve industry-standard margins [54][56] Other Important Information - The company has captured over $95 million in gross savings year-to-date, contributing to improvements in EBITDA [29] - The introduction of new technology and AI initiatives is expected to enhance productivity and operational excellence [11][12] Q&A Session Summary Question: Update on pre-spend vs post-spend awards - Management noted that there has been progress in right-sizing contracts and focusing on out-of-scope work, with improved results from these efforts [32][33] Question: Details on new-to-Fortrea clients - RFP volume from new clients increased by almost 40% quarter-over-quarter, with win rates for biotech clients doubling [37][38] Question: Bookings backdrop between large pharma and small biotech - Management observed neutral to favorable trends in both segments, with improved decision-making timelines in biotech [39][40] Question: Changes in competitive intensity and pricing environment - The pricing environment remains competitive but disciplined, with a focus on leading with science and operational expertise rather than aggressive pricing [41] Question: Margin leverage and pricing strategy - Management aims to hold prices where possible, with a focus on growing direct service fee revenue to improve margins [45][46] Question: Anecdotes on industry environment - Positive anecdotes were shared regarding decision-making timelines in both biotech and large pharma, indicating a return to more stable operational processes [62]